Salute e Benessere

Breast Fillers Market to Reach $728.7 million, Globally, by 2034 at 6.3% CAGR…

Breast fillers are gaining popularity due to their customizable results, fewer complications, and increasing demand for natural looking enhancements. Advancements in filler technology and growing aesthetic consciousness, particularly among younger women, are driving market growth globally. Breast fillers are gaining popularity due to their customizable results, fewer complications, and increasing demand for natural looking enhancements. Advancements in filler technology and growing aesthetic...
PR Newswire
14/10/2025

Molecular Cytogenetics Market worth $1.43 billion in 2030 7.1% CAGR |…

Browse in-depth TOC on "Molecular Cytogenetics Market" Browse in-depth TOC on "Molecular Cytogenetics Market" 139 - Tables 45 - Figures 235 - Pages By product & service,the molecular cytogenetics market is segmented into kits & reagents, instruments, consumables, and software & services. Kits & reagents are expected to record the fastest growth during the forecast period. This surge is driven by their significant role in research, diagnostics, and...
PR Newswire
14/10/2025

Conformal Medical Announces First Patient Enrollment in the E.U. for CONFORM…

The CONFORM Pivotal Trial is evaluating the CLAAS® AcuFORM™ LAAO device, a novel foam-based implant designed to provide a simplified, anatomy-conforming solution for stroke prevention in patients with non-valvular atrial fibrillation (AFib). The CONFORM Pivotal Trial is evaluating the CLAAS ®AcuFORM ™LAAO device, a novel foam-based implant designed to provide a simplified, anatomy-conforming solution for stroke prevention in patients with non-valvular atrial fibrillation (AFib). ...
PR Newswire
14/10/2025

Medical Second Opinion Market Size to Reach USD 12.7 Billion by 2031 Amid Rising…

Digital health platforms, telemedicine, artificial intelligence (AI), and global specialist networks are enabling faster, more accurate, and more affordable access to expert medical opinions-making this market one of the fastest-growing sectors in healthcare services. Digital health platforms, telemedicine, artificial intelligence (AI), and global specialist networks are enablingfaster, more accurate, and more affordableaccess to expert medical opinions-making this market one of the...
PR Newswire
14/10/2025

/C O R R E C T I O N -- iOnctura/

Lead investigator, Davide Melisi, M.D., Ph.D, Associate Professor of Medical Oncology, and Director of the Digestive Molecular and Clinical Oncology Research Unit, University of Verona, and Investigational Cancer Therapeutics Clinical Unit at the University Hospital of Verona, Verona, Italy said, "These early findings with cambritaxestat are encouraging. Clinical activity alongside a manageable safety profile is particularly meaningful in a disease as aggressive and fibrotic as metastatic…
PR Newswire
14/10/2025

Quotient Sciences and Biorasi partner to accelerate early phase clinical trials…

The partnership will combine Quotient Sciences' expertise inearly clinical developmentwith Biorasi's global patient recruitment capabilities to provide biotech and pharma Sponsors with a simplified, efficient pathway from Investigational New Drug (IND) to proof-of-concept (POC) with seamless transitions from healthy volunteers into patient groups within first-in-human (FIH) Phase I/IIa clinical trials. Sponsors will benefit from Quotient Sciences' clinical pharmacology expertise,...
PR Newswire
14/10/2025

Pictor's Proteomics Platform Offers Promising Advancement for Detecting…

The research, conducted with funding from New Zealand's Ministry for Primary Industries and the University of Melbourne, demonstrates excellent analytical performance and a high level of agreement with existing methods. The PictVet™ assay achieved a Positive Percent Agreement (PPA) of 100%, a Negative Percent Agreement (NPA) of 98.4%, and an overall agreement of 98.9% compared to the IDvet ELISA. This performance is supported by a unique multiplex design that uses two distinct Mycoplasma bovis…
PR Newswire
14/10/2025

India's No:1 Ranked Institute IIT Madras partners with Hyundai Motor India to…

At the heart of this initiative is the Hyundai Centre for Cancer Genomics, housed at IIT Madras. It will also serve as a collaborative hub for clinicians, researchers, pharmaceutical scientists, and global partners, contributing to international efforts such as the International Cancer Genome Consortium (ICGC) and WHO's International Agency for Research on Cancer (IARC). At the heart of this initiative is the Hyundai Centre for Cancer Genomics, housed at IIT Madras.It will also serve as a...
PR Newswire
14/10/2025

KVP International Strengthens Its Global Position with Rapid EU and Latin…

The company, already serving over 30 countries worldwide, continues to report record global sales and strong growth across both established and emerging markets. The company, already serving over 30 countries worldwide, continues to report record global sales and strong growth across both established and emerging markets. Over the past year, KVP has added eight (8) new distributor partners across the European Union, three (3) new major distributors inLatin America, expanded its product...
PR Newswire
14/10/2025

Caristo Chosen by Leading Pharma Company as Worldwide Imaging Core Lab to…

The REMBRANDT trial, sponsored by NewAmsterdam Pharma (Nasdaq: NAMS), is a placebo-controlled, double-blind, randomized trial designed to assess the efficacy of obicetrapib and ezetimibe fixed dose combination (FDC) on coronary plaque burden. Obicetrapib is an investigational cholesteryl ester transfer protein (CETP) inhibitor that has shown to lower low-density lipoprotein cholesterol (LDL-C) in three Phase 3 clinical trials. Favorable changes in noncalcified coronary atherosclerotic plaque…
PR Newswire
14/10/2025

Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2025

Company Announcement Net sales of DARZALEX ®in the third quarter of 2025 totaled USD 3,672 millionGenmab receives royalties on worldwide net sales from Johnson & Johnson (J&J, legal entity Janssen Biotech, Inc.)COPENHAGEN, Denmark; October 14, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of DARZALEX (daratumumab), including sales of the subcutaneous (SC) product (daratumumab and hyaluronidase-fihj , sold under the...
Nasdaq GlobeNewswire
14/10/2025

Digital Health Market Segmentation: Key Technologies, Growth Factors, and Market…

Transparency Market Research
14/10/2025

11 Years of Global Patient Week: Bristol Myers Squibb Brings Joy to Patients…

The act of engaging with toys holds significant therapeutic value for children, fostering imagination, promoting emotional well-being, and supporting healthy development. In these workshops employees created superhero toys from scratch, a powerful symbol of the strength and resilience of young patients navigating their treatment journeys. By engaging in this creative and hands-on activity, Bristol Myers Squibb employees reaffirmed their commitment to supporting patients beyond medicine, bringing…
PR Newswire
14/10/2025

iOnctura debuts cambritaxestat (IOA-28G) clinical data in patients with…

The Phase Ib dose escalation study, AION-02 (NCT05586516) evaluated cambritaxestat in combination with standard-of-care chemotherapy GnP in patients with previously untreated mPDAC. Sixteen patients received cambritaxestat orally, twice daily at doses of 100 mg (n=4), 200 mg (n=4), 400 mg (n=5) and 800 mg (n=3). GnP was administered by IV infusion, weekly for three weeks of a four-week cycle. The Phase Ib dose escalation study, AION-02 (NCT05586516 )evaluated cambritaxestat in combination...
PR Newswire
14/10/2025

Orion publishes Interim Report for January–September 2025 and holds a webcast on…

ORION CORPORATIONPRESS RELEASE14 OCTOBER 2025 at 11.15 EEST Orion publishes Interim Report for January–September 2025 and holds a webcast on 28 October 2025 Orion will publish Interim Report for January–September 2025 on Tuesday, 28 October 2025 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website atwww.orionpharma.com/investorsafter publishing. Webcast and conference call A webcast and a...
Nasdaq GlobeNewswire
14/10/2025

From Silicon Valley to Mainstream Medicine: How elegant hoopoe 'Longevity…

What began as an elite trend among tech executives and athletes has evolved into a fundamental shift in how people approach health. Analysis of 61+ million social posts reveals biohacking has gone mainstream, with consumer conversations around blood sugar management and personalised supplementation rising 30% and 27% annually (source). What began as an elite trend among tech executives and athletes has evolved into a fundamental shift in how people approach health. Analysis of 61+…
PR Newswire
14/10/2025

ILIKOS and Zapyrus have partnered to equip MedTech CRO business development…

In a market where innovation cycles are tightening and competition for customer attention is fierce, business development teams must rely on more than just instinct. It is critical that they utilize a data-driven, execution-ready approach combined with consistency, persistence and industry knowledge. This partnership merges ILIKOS' recognized expertise in building and implementing tailored business development methodologies with Zapyrus' leading sales and market intelligence platform, which…
PR Newswire
14/10/2025

Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO…

/ XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today announced that Oculis’ innovative late-stage pipeline will be highlighted at Eyecelerator and at the American Academy of Ophthalmology (AAO) Annual Meeting. At Eyecelerator, Riad Sherif, MD, Oculis’ Chief Executive Officer, will provide an update on the Company’s innovative late-stage pipeline. Featured updates...
Nasdaq GlobeNewswire
14/10/2025

Actithera Secures Exclusive Rights to Innovative Covalent Chemistry Technologies…

"This agreement represents an important step forward for Actithera," said Andreas Goutopoulos, PhD, Founder and Chief Executive Officer ofActithera. "By adding Professor London's pioneering chemistry to our toolkit of proprietary covalent and non-covalent approaches, we are uniquely positioned to unlock new opportunities in cancer treatment. This innovation from the Weizmann Institute enables us to introduce radioactivity directly into tumor cells by irreversibly and tracelessly…
PR Newswire
14/10/2025

First patient treated with Leqembi® (lecanemab) in the Nordics

Leqembi received the European Commission (EC) approval in April 2025 as the first therapy that targets an underlying cause of Alzheimer's disease (AD). It is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment (MCI) and mild dementia due to AD (early AD) who are apolipoprotein E ε4 (ApoE ε4[1]) non-carriers or heterozygotes with confirmed amyloid pathology.[2] Leqembi received the European Commission (EC) approval inApril 2025as the first...
PR Newswire
14/10/2025

Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as…

At Daiichi Sankyo, Dr. Yver served as Global Head of Oncology R&D, and at AstraZeneca, he led the oncology development programs. His leadership in bringing ENHERTU, a pioneering ADC for breast cancer, from initial first-in-human clinical studies to global approval, exemplifies his deep expertise and will be invaluable to Ona as it advances its innovative ADC pipeline toward clinical development. At Daiichi Sankyo, Dr. Yver served as Global Head of Oncology R&D, and at AstraZeneca, he…
PR Newswire
14/10/2025

EVerZom raises €10M to develop exosome-based biotherapies for inflammatory…

Press Release Press ReleaseEVerZom raises €10M to develop exosome-based biotherapies for inflammatory diseasesThrough this funding round, the company will initiate the clinical development of its first therapeutic candidate,EVerGel, in 2026, and will enhance its exosome biomanufacturing platform to advance its regenerative medicine programs.Strasbourg, October 14 th, 2025 –EVerZom, a French biotechnology company pioneering exosome-based therapies for...
Nasdaq GlobeNewswire
14/10/2025

United Imaging Showcases Advanced Molecular Imaging Innovations and Highlights…

Notably, this September, Centres de Médecine Nucléaire du Morbihan (CMNM), part of Lutetia Care Group an important network of nuclear medicine centers in France, introduced the uMI Panvivo. "From the very first scans, the whole team understood how much this machine was going to revolutionize our practices," said Dr. Erwann Gabiache, Medical-Scientific Director at Lutecia Care. Notably, this September, Centres de Médecine Nucléaire du Morbihan (CMNM), part of Lutetia Care Group an…
PR Newswire
14/10/2025

AB Science will hold a virtual conference on Thursday, October 16, 2025 from 2pm…

PRESS RELEASEAB SCIENCE RELEASES INITIAL DATA ON THE COMBINATION OF AB8939 WITH VENETOCLAX FOR THE TREATMENT OF REFRACTORY OR RELAPSED ACUTE MYELOID LEUKEMIA (AML): THE FIRST THREE PATIENTS, ALL OF WHOM HAVE AML WITH VERY UNFAVORABLE GENETIC PROFILES, ARE RESPONDING TO TREATMENTThe combination treatment is well-tolerated, with no hematological toxicityThe disease control rate is 100% (3/3)The partial response rate is 100% (3/3), including one patient in complete remission These...
Nasdaq GlobeNewswire
14/10/2025
Altri  Comunicati